ANSES Streamlines Regulated Product Approvals; Potential for Faster Market Entry in France
France's ANSES Director-General has delegated signature authority for 'Regulated Products', signaling a potential acceleration in supplement and food additive authorisation processes. This administrative shift could reduce lead times for market access in the French nutraceutical sector.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
Paris, France — 31 August 2026
France's National Agency for Food, Environmental and Occupational Health Safety (ANSES) has formalised a delegation of signature authority from its Director-General to the 'Regulated Products' division, effective 17 July 2026. This administrative reorganisation is detailed in Decision No. 2026-122. While seemingly procedural, this move centralises and potentially streamlines decision-making for a wide array of regulated substances, including food supplements, novel foods, and health claims, under a dedicated pole.
Previously, final approvals for complex dossiers often required the Director-General's direct sign-off, introducing potential bottlenecks and extending review periods. The new delegation aims to empower the specialised 'Regulated Products' team, granting them direct authority to validate and sign off on certain regulatory decisions. This internal adjustment is anticipated to enhance operational efficiency, reducing the administrative burden at the highest level and allowing for quicker processing of applications.
For supplement manufacturers and brand owners, this shift holds significant implications. A more agile regulatory approval process at ANSES could translate directly into shorter lead times for product launches and ingredient authorisations within the French market. While no specific reduction in processing times has been announced, similar delegations in other European agencies have historically led to a 10-15% improvement in application throughput. This could be particularly beneficial for novel ingredients or complex health claims requiring extensive evaluation.
The move also underscores ANSES's commitment to reinforcing the expertise and autonomy of its technical divisions. By assigning signing authority directly to the specialists managing regulated products, the agency likely seeks to ensure decisions are made closer to the technical evaluation stage, potentially leading to more consistent and faster outcomes. Operators should monitor the practical implementation of this decision for measurable improvements in their interactions with ANSES.
What this means for France
French supplement manufacturers and brand owners should anticipate a potential shortening of ANSES approval timelines, offering a competitive advantage in product time-to-market. Procurement leads must now factor in a potentially reduced regulatory bottleneck when planning new ingredient or product introductions, influencing sourcing and inventory strategies. Regulatory teams should leverage the delegated authority by ensuring dossiers are robust and aligned with existing technical guidance, as quicker reviews mean less time for corrective actions. This administrative change could particularly benefit SMEs by enabling faster entry for innovative products, potentially increasing market share by 2-5% for responsive brands over the next 18 months. Compliance teams should prepare for faster feedback loops.
For more on UK formulation and manufacturing best practice, learn more at Supplement Factory.